Literature DB >> 10598666

Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma.

H C Rossbach1, A Lacson, N H Grana, J L Barbosa.   

Abstract

The authors report the concomitant occurrence of Duchenne muscular dystrophy (DMD) and alveolar rhabdomyosarcoma (RMS). A 4-year-old boy presented with symptoms involving his neuromuscular system that affected primarily his left hip and leg. Duchenne muscular dystrophy was diagnosed. Seven months later, metastatic alveolar RMS in the ipsilateral pelvis was documented. The diagnosis of one major disorder affecting striated muscle (DMD) may have prevented the early detection of another (RMS).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598666

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  10 in total

Review 1.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

2.  Medulloblastoma in a child with Duchenne muscular dystrophy.

Authors:  Harsha Doddihal; Rakesh Jalali
Journal:  Childs Nerv Syst       Date:  2006-12-23       Impact factor: 1.475

3.  Muscle Stem Cells Give Rise to Rhabdomyosarcomas in a Severe Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Francesca Boscolo Sesillo; David Fox; Alessandra Sacco
Journal:  Cell Rep       Date:  2019-01-15       Impact factor: 9.423

Review 4.  High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.

Authors:  Frank Peinemann; Nicolaus Kröger; Carmen Bartel; Ulrich Grouven; Max Pittler; Rudolf Erttmann; Michael Kulig
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

5.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 6.  The Duchenne muscular dystrophy gene and cancer.

Authors:  Leanne Jones; Michael Naidoo; Lee R Machado; Karen Anthony
Journal:  Cell Oncol (Dordr)       Date:  2020-11-14       Impact factor: 6.730

7.  Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Authors:  Yuexiang Wang; Adrian Marino-Enriquez; Richard R Bennett; Meijun Zhu; Yiping Shen; Grant Eilers; Jen-Chieh Lee; Joern Henze; Benjamin S Fletcher; Zhizhan Gu; Edward A Fox; Cristina R Antonescu; Christopher D M Fletcher; Xiangqian Guo; Chandrajit P Raut; George D Demetri; Matt van de Rijn; Tamas Ordog; Louis M Kunkel; Jonathan A Fletcher
Journal:  Nat Genet       Date:  2014-05-04       Impact factor: 38.330

8.  DMD transcripts in CRL-2061 rhabdomyosarcoma cells show high levels of intron retention by intron-specific PCR amplification.

Authors:  Emma Tabe Eko Niba; Ryo Yamanaka; Abdul Qawee Mahyoob Rani; Hiroyuki Awano; Masaaki Matsumoto; Hisahide Nishio; Masafumi Matsuo
Journal:  Cancer Cell Int       Date:  2017-05-23       Impact factor: 5.722

Review 9.  Cellular pathology of the human heart in Duchenne muscular dystrophy (DMD): lessons learned from in vitro modeling.

Authors:  Albano C Meli; Vladimir Rotrekl; Barbora Svobodova; Sarka Jelinkova; Martin Pesl; Deborah Beckerová; Alain Lacampagne
Journal:  Pflugers Arch       Date:  2021-06-24       Impact factor: 3.657

10.  Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes.

Authors:  Petr Dmitriev; Ulykbek Kairov; Thomas Robert; Ana Barat; Vladimir Lazar; Gilles Carnac; Dalila Laoudj-Chenivesse; Yegor S Vassetzky
Journal:  J Cell Mol Med       Date:  2013-12-17       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.